DENVER, Colo. (247marketnews.com) -- OmniAb (NASDAQ:OABI) may be one of the more interesting picks-and-shovels stories emerging in biotech, and its latest deal with Eli Lilly & Company (NYSE:LLY) could be another indication that the pharmaceutical industry sees value in the company’s technology rather than simply another early-stage drug program.
OmniAb announced a global collaboration and license agreement with Lilly for a new ion-channel program, leveraging OmniAb’s ion-channel discovery and screening capabilities. The financial terms include an upfront payment, up to $370 million in research, development and commercial milestones, plus tiered royalties on global net sales. The target and therapeutic modality remain undisclosed.
Matt Foehr, OmniAb’s CEO, stated, “Lilly is focused on delivering medicines to address major unmet medical needs and our differentiated expertise and established technologies that relate to ion channels are well positioned to help drive this new discovery program.”
OmniAb isn't trying to become the next biotech with one binary drug candidate. Its business model is built around providing pharmaceutical and biotechnology companies with discovery technologies designed to help identify therapeutic candidates. The company says more than 100 biopharmaceutical companies and research institutions are using its technologies, while its pipeline includes programs partnered with major pharmaceutical companies including Johnson & Johnson, Pfizer, Genentech, Merck, AstraZeneca, AbbVie and others.
That creates a potentially powerful “platform economics” model: OmniAb can participate in multiple drug-development programs without having to finance every downstream clinical trial itself. Its agreements can generate upfront payments, research or service revenue, milestones and, potentially, royalties if partnered programs reach commercialization.
The Lilly agreement arrives at an especially interesting time because OmniAb has also raised its 2026 cash outlook to $49 million–$53 million, from $37 million–$41 million previously, citing recent business-development and licensing activity. Management has described the growing partner ecosystem as evidence that its technologies are gaining broader reach.
“We’ve built a suite of highly-differentiated and cutting-edge technologies that are designed to efficiently enable the next generation of global medicines,” said Todd Pettingill, OmniAb’s Vice President of Business Development & Strategy.
The company’s technology stack extends beyond traditional antibody discovery. OmniAb combines proprietary transgenic animal platforms, including OmniRat, OmniMouse and OmniChicken, with high-throughput screening, computational tools and AI-driven discovery capabilities. Its ion-channel expertise is particularly notable because ion channels are historically difficult therapeutic targets, and OmniAb has built specialized assays and antigen-design capabilities around challenging membrane proteins.
For a discovery-platform company, every major pharmaceutical partnership can potentially expand the company's validation, pipeline and future royalty opportunity. If more programs advance, today's relatively modest discovery agreements can potentially become tomorrow's recurring milestone and royalty engine.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.